» Articles » PMID: 35924851

Mucosal Immune Profiles Associated with Diarrheal Disease Severity in - and Enteropathogenic Escherichia Coli-Infected Children Enrolled in the Global Enteric Multicenter Study

Abstract

Enteropathogenic Escherichia coli (EPEC) and are etiologic agents of diarrhea in children <5 years old living in resource-poor countries. Repeated bouts of infection lead to lifelong morbidity and even death. The goal of this study was to characterize local mucosal immune responses in - and EPEC-infected children <5 years of age with moderate to severe diarrhea (MSD) enrolled in the Global Enteric Multicenter Study (GEMS). We hypothesized that infection with each of these pathogens would induce distinct gut mucosal immune profiles indicative of disease etiology and severity. To test this hypothesis, innate and adaptive immune markers were measured in stools from children with diarrhea due to EPEC, , or other organisms and in children who had no diarrhea. positive diarrhea evoked robust proinflammatory and T1/T2 cytokine responses compared to diarrhea caused by EPEC or other organisms, with the exception of interleukin 5 (IL-5), which was associated with EPEC infection. The presence of IL-1β, IL-4, IL-16, and tumor necrosis factor beta (TNF-β) was associated with the absence of dysentery. EPEC-positive diarrhea evoked high levels of IL-1β, vascular endothelial growth factor (VEGF), and IL-10. Granulocyte-macrophage colony-stimulating factor (GM-CSF) had opposing roles in disease severity, being associated with absence of diarrhea in EPEC-infected children and with dysenteric infection. High levels of antigen-specific antibodies were detected in the controls and children with without dysentery, which suggests a protective role against severe disease. In summary, this study identified distinct local immune responses associated with two clinically relevant diarrheagenic pathogens, and EPEC, in children and identified protective immune phenotypes that can inform the development of preventive measures. and enteropathogenic Escherichia coli are primary agents of moderate to severe diarrhea in children <5 years of age living in resource-poor countries. Repeated bouts of illness lead to lifelong health impairment and even death. Aiming to understand the local host immunity to these pathogens in relation to disease prognosis and to identify prophylaxis and therapeutic targets, we investigated innate and adaptive immune profiles in stools from children infected with EPEC with and without diarrhea, with and without dysentery, and controls in well characterized clinical samples obtained during the Global Enteric Multicenter Study. For the first time, we report pathogen-specific mucosal immune profiles associated with severity or absence of disease in children <5 years of age that can inform prevention and treatment efforts.

Citing Articles

016 Alleviates Mice Colitis by Modulating Oxidative Stress, Gut Microbiota, and Microbial Metabolism.

Pan H, Yang S, Kulyar M, Ma H, Li K, Zhang L Nutrients. 2025; 17(3).

PMID: 39940311 PMC: 11820689. DOI: 10.3390/nu17030452.


Antibiogram profiles of pathogenic and commensal bacteria in goat and sheep feces on smallholder farm.

Basnet A, Kilonzo-Nthenge A Front Antibiot. 2025; 3():1351725.

PMID: 39816253 PMC: 11732006. DOI: 10.3389/frabi.2024.1351725.


Safety and Tolerability of ShigActive™, a spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial.

Chen W, Woolston J, Grant-Beurmann S, Robinson C, Bansal G, Nkeze J Antibiotics (Basel). 2024; 13(9).

PMID: 39335031 PMC: 11429168. DOI: 10.3390/antibiotics13090858.


Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer.

Dougan M, Nguyen L, Buchbinder E, Lazarus H Cancers (Basel). 2024; 16(3).

PMID: 38339253 PMC: 10854719. DOI: 10.3390/cancers16030501.


Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate.

Desalegn G, Tamilselvi C, Lemme-Dumit J, Heine S, Dunn D, Ndungo E NPJ Vaccines. 2024; 9(1):2.

PMID: 38167387 PMC: 10761965. DOI: 10.1038/s41541-023-00797-6.


References
1.
Carayol N, Tran van Nhieu G . The inside story of Shigella invasion of intestinal epithelial cells. Cold Spring Harb Perspect Med. 2013; 3(10):a016717. PMC: 3784809. DOI: 10.1101/cshperspect.a016717. View

2.
Bennett Jr W, Gonzalez-Rivera R, Puente B, Shaikh N, Stevens H, Mooney J . Proinflammatory fecal mRNA and childhood bacterial enteric infections. Gut Microbes. 2011; 1(4):209-212. PMC: 3023602. DOI: 10.4161/gmic.1.4.13004. View

3.
Ma X, Sartori A, Trinchieri G . Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol. 1998; 160(12):5936-44. View

4.
Philpott D, Edgeworth J, Sansonetti P . The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies. Philos Trans R Soc Lond B Biol Sci. 2000; 355(1397):575-86. PMC: 1692768. DOI: 10.1098/rstb.2000.0599. View

5.
Dean-Nystrom E, Gansheroff L, Mills M, Moon H, OBrien A . Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun. 2002; 70(5):2414-8. PMC: 127944. DOI: 10.1128/IAI.70.5.2414-2418.2002. View